Sevil Aliyeva, MD
Endocrinology, Diabetes & Metabolism · Waldorf, MDNPI 1285029215
Payments from drug & device makers
Across 187 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$689
- Novo Nordisk$449
- Sanofi-aventis U.S. LLC$261
- Corcept Therapeutics$254
- Amneal Pharmaceuticals LLC$233
- AstraZeneca$210
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,97198%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 35 | $689 |
| Novo Nordisk | 23 | $449 |
| Sanofi-aventis U.S. LLC | 11 | $261 |
| Corcept Therapeutics | 8 | $254 |
| Amneal Pharmaceuticals LLC | 12 | $233 |
| AstraZeneca(2 entities) | 12 | $210 |
| Amgen | 11 | $202 |
| Insulet Corporation | 10 | $200 |
| AbbVie | 9 | $197 |
| Boehringer Ingelheim | 8 | $168 |
| Abbott | 5 | $108 |
| BETA Bionics, Inc. | 5 | $108 |
| Xeris Pharmaceuticals, Inc. | 5 | $106 |
| Tandem Diabetes Care, Inc. | 4 | $98 |
| Sequel Med Tech, LLC | 4 | $96 |
| Exelixis Inc. | 1 | $87 |
| Lifescan, Inc. | 3 | $75 |
| Dexcom, Inc. | 4 | $70 |
| Madrigal Pharmaceuticals | 2 | $65 |
| Zealand Pharma US, Inc. | 2 | $50 |
| IBSA Pharma Inc. | 2 | $49 |
| Cequr Corporation | 1 | $43 |
| Recordati_rare_diseases_inc. | 2 | $41 |
| Ascensia Diabetes Care US Inc. | 1 | $36 |
| Novartis | 2 | $34 |
| Merck | 2 | $32 |
| Medtronic | 1 | $30 |
| Acella Pharmaceuticals, LLC | 1 | $23 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$103
How this compares
$4,036 in reported general payments places this provider in the 65th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 99 | $181,326 |
| MounjaroTirzepatide | 97 | $171,796 |
| JardianceEmpagliflozin | 44 | $72,273 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 26 | $33,630 |
| FarxigaDapagliflozin Propanediol | 19 | $30,564 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $26,523 |
| TrulicityDulaglutide | 13 | $25,676 |
| ProliaDenosumab | 11 | $19,218 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $16,327 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $13,169 |
| Novolog FlexpenInsulin Aspart | 23 | $9,221 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 32 | $6,046 |
| SynthroidLevothyroxine Sodium | 75 | $5,163 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $3,300 |
| Levothyroxine Sodium | 119 | $1,073 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $689 | $197,472110 claims |
| Novo NordiskOzempic | $449 | $181,32699 claims |
| Boehringer IngelheimJardiance | $168 | $72,27344 claims |
| AstraZenecaFarxiga | $210 | $30,56419 claims |
| AmgenProlia | $202 | $19,21811 claims |
| AbbVieSynthroid | $197 | $5,16375 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $233 | $1,073119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Waldorf
- Jean ParkBaltimore$3.7M
- Michael DempseyRockville$2.7M
- Ilias SpanakisBaltimore$2.6M
- Helena RodbardRockville$2.4M
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Romeu AzevedoCamp Springs$1.1M
- Nicholas ArgentoLaurel$1.1M
- Philip LevinBaltimore$702K
- David BrownRockville$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.